UK incidence of indicated cancers, and estimates of total numbers eligible for treatment with selected medicine
| Medicine | Incidence by ICD-10 category | Indication of medicine, and proportion of relevant ICD-10 group | Eligibility in terms of pathology, and percentage of incident cases with this subtype | Eligibility in terms of stage of disease, a percentage of incident cases at this stage | Total number eligible for indication, per year | Total number eligible for medicine, per year |
|---|---|---|---|---|---|---|
| Bortezomib | Multiple myeloma, 4792 | – | – | Relapsed, received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation, 25.5% | 1222 | 6014 |
| Multiple myeloma, 4792 | – | – | Patients for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate, 86.4% | 4140 | ||
| Multiple myeloma, 4792 | – | – | Patients for whom high-dose chemotherapy with stem cell transplantation is considered appropriate, 13.6% | 652 | ||
| Dasatinib | Chronic myeloid leukaemia, 675 | – | Philadelphia chromosome-positive, 87.5% | Chronic phase, 90% | 532 | 817 |
| Chronic myeloid leukaemia, 675 | – | Philadelphia chromosome-positive, 87.5% | Intolerant or resistant to imatinib, 40% | 236 | ||
| Acute lymphoblastic leukaemia, 654 | – | Philadelphia chromosome-positive, 25% | Refractory to imatinib, 30% | 49 | ||
| Everolimus | Kidney, 10 144 | Renal cell carcinoma, 85% | Clear cell renal cell carcinoma, 77.5% | Advanced/metastatic, 71.5% | 6165 | 9780 |
| Kidney, 10 144 | Renal cell carcinoma, 85% | Non-clear cell renal cell carcinoma, 22.5% | Advanced/metastatic, 71.5% | 1790 | ||
| Breast, 50 285 | – | Advanced/metastatic, 29.5% | HER2 negative, postaromatase inhibitor, 12.3% | 1825 | ||
| Gefitinib | Lung cancer, 44 488 | Non-small cell lung cancer, 85% | EGFR positive, 22.5% | Advanced/metastatic, 83.5% | 7104 | 7104 |
Advanced pancreatic neuroendocrine and tuberous sclerosis, for which everolimus is an indicated treatment in some cases, has not been included, due to its relative rarity. Bortezomib is indicated in some cases of mantle cell lymphoma. This has not been included due to lack of available data.